Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Moneer Eddin

Cardiovascular Disease Lancaster, CA Medical Doctor

NPI 1073780938 CMS profile 94682

43723 20Th St W Ste 101, Lancaster, CA 93534

Open in the dashboard

General payments

$17,124

437 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Moneer Eddin of Lancaster, CA is reported in the CMS Open Payments database as having received $17,124 across 437 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,594 92
2024 General $2,190 79
2023 General $1,398 72
2022 General $1,360 52
2021 General $1,837 40
2020 General $1,654 44
2019 General $2,091 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Moneer Eddin
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Moneer Eddin were reported at $6,594. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Moneer Eddin Cardiovascular Disease median Middle half National median
2019 $2,091 $450 $127–$1,392 $163
2020 $1,654 $242 $77–$751 $114
2021 $1,837 $335 $101–$1,037 $132
2022 $1,360 $395 $121–$1,211 $149
2023 $1,398 $443 $136–$1,283 $160
2024 $2,190 $450 $136–$1,323 $164
2025 $6,594 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $4,442 85 payments
  2. Edwards Lifesciences Corporation $2,951 30 payments
  3. Medtronic, Inc. $2,020 22 payments
  4. Abbott Laboratories $1,365 16 payments
  5. Amgen Inc. $868 33 payments
  6. Abiomed $831 24 payments
  7. Boston Scientific Corporation $746 29 payments
  8. Merck Sharp & Dohme Corporation $740 30 payments
  9. AstraZeneca Pharmaceuticals LP $461 27 payments
  10. Pfizer Inc. $459 31 payments
  11. Other $2,241 110 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,131 420 payments
  2. Travel and Lodging $3,730 13 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,250 3 payments
  4. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. LifeVest $4,442 85 payments
  2. EVERA MRI XT DR SURESCAN $1,360 7 payments
  3. TRICLIP $1,137 9 payments
  4. SAPIEN 3 Ultra RESILIA $966 12 payments
  5. Repatha $868 33 payments
  6. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $863 10 payments
  7. VERQUVO $857 35 payments
  8. Impella $753 21 payments
  9. Corlanor $512 18 payments
  10. WATCHMAN Access System $455 12 payments
  11. Other $5,082 247 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

2,995

Median for Internal Medicine: 777

Drug cost

$430,064

Median for Internal Medicine: $73,373

Branded share of claims

24%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 185 $148,857
Entresto Sacubitril/Valsartan Brand 83 $75,266
Farxiga Dapagliflozin Propanediol Brand 83 $53,520
Xarelto Rivaroxaban Brand 40 $48,715
Jardiance Empagliflozin Brand 60 $40,723
Repatha Sureclick Evolocumab Brand 15 $12,569
Brilinta Ticagrelor Brand 13 $10,272
Verquvo Vericiguat Brand 11 $8,469
Praluent Pen Alirocumab Brand 17 $8,189
Atorvastatin Calcium Generic 254 $2,310

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$318,063

Of which drugs: $2,107

Medicare patients

782

Average age 73

Services billed

2,716

383 women, 399 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 56%
Ischemic heart disease 47%
Heart failure 42%
COPD 39%
Chronic kidney disease 38%
Atrial fibrillation 33%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 96 384 $2,101

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $141
$141 11 —
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $125
$125 — —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $101
$101 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $98
$98 60 —
ONPATTRO
  • Alnylam Pharmaceuticals Inc. $84
$84 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

437 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record